A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

November 24, 2017

Primary Completion Date

August 31, 2022

Study Completion Date

September 23, 2022

Conditions
Macular Telangiectasia Type 2 (MacTel)
Interventions
COMBINATION_PRODUCT

NT-501

"Each NT-501 implant consisted of hCNTF-secreting NTC-201-6A.02 cells encapsulated within supportive matrices and surrounded by a semipermeable polymer membrane.~The NTC-201-6A cells continuously secrete CNTF from the NT-501 implant into the vitreous cavity. Implanted by a qualified Health Care Professional."

PROCEDURE

Sham Procedure

The sham surgery involved a superficial conjunctival incision performed under local anesthetic and closure with a single suture.

Trial Locations (20)

6009

Lions Eye Institute, Perth

20892

National Institute of Health, NIH, Bethesda

21740

Cumberland Valley Retina Consultants, Hagerstown

37922

Southeastern Retina Associates, PC, Knoxville

44122

Retina Associates of Cleveland, Inc., Cleveland

48073

Associated Retinal Consultants, P.C., Royal Oak

70006

Retina Associates of New Orleans, Metairie

74114

Tulsa Retina Consultants, Tulsa

75010

Lariboisiere Hospital, Paris

75231

Texas Retina Associates, Dallas

80909

Retina Consultants of Southern Colorado, P.C., Colorado Springs

84132

University of Utah John A. Moran Eye Center, Salt Lake City

89502

Sierra Eye Associates, Reno

90095

Jules Stein Eye Institute / David Geffen School of Medicine, Los Angeles

92037

Scripps Clinic Medical Group, La Jolla

94303

Byers Eye Institute at Stanford University, Palo Alto

94598

Bay Area Retina Associates, Walnut Creek

97221

Retina Northwest, PC, Portland

OX3 9DU

Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford

EC1V 2PD

Moorfields Eye Hospital NHS Foundation Trust, London

Sponsors
All Listed Sponsors
collaborator

The Lowy Medical Research Institute Limited

OTHER

lead

Neurotech Pharmaceuticals

INDUSTRY